Immunic Therapeutics has been granted a new patent in Europe covering multiple dosing regimens of its experimental therapy vidofludimus calcium and related molecules for multiple sclerosis (MS) and other indications. The patent, titled “Dosage Regimen of Vidofludimus for Use in the Treatment of a Chronic Inflammatory…
Discussion
In the not-too-distant past, when my hands were still deft enough to use tools, I really enjoyed working on vehicles. The fact that they weren’t vehicles I depended on every day helped make it a hobby I enjoyed, rather than a chore. Like any hobby, it had its dull moments,…
Loss of brain volume (brain atrophy), a measure often used in clinical trials to track disease progression, may not accurately reflect worsening disability in people with primary progressive multiple sclerosis (PPMS). That’s according to a new analysis of data from the Phase 3 PROMISE trial, in which measures of…
Although the total number of people living with multiple sclerosis (MS) has increased globally in recent decades due to population growth and aging, MS is causing fewer deaths and less disability now than in the past, according to a new study. Predictions also suggest that this trend toward reduced…
Discussion
Dealing with multiple sclerosis (MS) — including the numerous symptoms that manifest differently for each person, the grief, and the uncertainty — is grueling. On top of all that, there’s the added challenge of navigating the American healthcare system. As I have written before, I’ve dealt with migraines…
Get regular updates to your inbox.
